Cargando…

It is time to consider third-line options in antiretroviral-experienced paediatric patients?

BACKGROUND: The historic use of full-dose ritonavir as part of an unboosted protease inhibitor (PI)-based antiretroviral therapy regimen in some South African children contributes to the frequent accumulation of major PI resistance mutations. METHODS: In order to describe the prevalence of major PI...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Zyl, Gert U, Rabie, Helena, Nuttall, James J, Cotton, Mark F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228719/ https://www.ncbi.nlm.nih.gov/pubmed/22085598 http://dx.doi.org/10.1186/1758-2652-14-55

Ejemplares similares

Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?
por: Frigati, Lisa Jane, et al.
Publicado: (2022)

Experiencing antiretroviral adherence: helping healthcare staff better understand adherence to paediatric antiretrovirals
por: Phelps, Benjamin R, et al.
Publicado: (2010)

Trends in paediatric bloodstream infections at a South African referral hospital
por: Dramowski, Angela, et al.
Publicado: (2015)

Approach to the management of paediatric HIV spontaneous controllers
por: Zuidewind, Peter, et al.
Publicado: (2022)

Optimised paediatric antiretroviral treatment to achieve the 95-95-95 goals
por: Archary, Moherndran, et al.
Publicado: (2021)

Use of Third Line Antiretroviral Therapy in Latin America
por: Cesar, Carina, et al.
Publicado: (2014)

Pelvic/Perineal Reconstruction: Time to Consider the Anterolateral Thigh Flap as a First-line Option?
por: Perrault, David, et al.
Publicado: (2020)

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
por: Meloni, Seema T, et al.
Publicado: (2017)

Considering paediatric radiology
por: Halliday, Katharine
Publicado: (2021)

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens
por: Van Zyl, Gert U., et al.
Publicado: (2013)

Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life
por: Laughton, Barbara, et al.
Publicado: (2019)

The end of the line? A case of drug resistance to third-line antiretroviral therapy
por: Rossouw, Theresa M., et al.
Publicado: (2016)

Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study
por: Hainline, Clotilde, et al.
Publicado: (2011)

Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India
por: Khan, Samsuddin, et al.
Publicado: (2014)

Delays in third-line antiretroviral therapy and outcomes in North West province
por: Majova, Babalwa, et al.
Publicado: (2022)

Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa
por: Onoya, Dorina, et al.
Publicado: (2017)

Universal children's day – let's improve current interventions to reduce vertical transmission of HIV now
por: Cotton, Mark F, et al.
Publicado: (2014)

Planning to introduce novel tuberculosis vaccines in high burden settings: how could this be done?
por: Cotton, Mark F, et al.
Publicado: (2023)

Resistance in Patients Failing Integrase Strand Transfer Inhibitors: A Call to Replace Raltegravir With Dolutegravir in Third-Line Treatment in South Africa
por: Steegen, Kim, et al.
Publicado: (2019)

Antiretroviral therapy during the neonatal period
por: Nuttall, James J.C.
Publicado: (2015)

Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis
por: Arvaniti, Pinelopi, et al.
Publicado: (2020)

HIV-1 Persistence in Children during Suppressive ART
por: Katusiime, Mary Grace, et al.
Publicado: (2021)

HIV testing and antiretroviral therapy initiation at birth: Views from a primary care setting in Khayelitsha
por: Nelson, Aurélie, et al.
Publicado: (2015)

A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy
por: Cohe, Karen, et al.
Publicado: (2019)

Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients
por: Patel, Dishank, et al.
Publicado: (2013)

The largest HIV-1-infected T cell clones in children on long-term combination antiretroviral therapy contain solo LTRs
por: Botha, Johannes C., et al.
Publicado: (2023)

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial
por: Zhao, Ying, et al.
Publicado: (2023)

Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes
por: Chimbetete, Cleophas, et al.
Publicado: (2020)

Estimating qualification and factors associated with third-line antiretroviral therapy referral in the Western Cape
por: Sheik, Sadiyya, et al.
Publicado: (2021)

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission
por: Nyakato, Patience, et al.
Publicado: (2020)

Rapid emergence of resistance to antiretroviral treatment after undisclosed prior exposure: A case report
por: Rossouw, Theresa M., et al.
Publicado: (2019)

Considering Options for Attenuating Postmeal Glucose Excursions
por: Wylie-Rosett, Judith, et al.
Publicado: (2010)

Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study
por: Meintjes, Graeme, et al.
Publicado: (2015)

HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon
por: Mbouyap, Pretty Rosereine, et al.
Publicado: (2023)

Retrospective Review of Virologic and Immunologic Response in Treatment-Experienced Patients on Third-Line HIV Therapy in Lusaka, Zambia
por: Zulu, Paul Msanzya, et al.
Publicado: (2021)

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
por: Keene, Claire M, et al.
Publicado: (2023)

A systematic review and meta-analysis assessing antiretroviral therapy for treatment-experienced HIV adult patients using an optimized background therapy approach: is there evidence enough for a standardized third-line strategy?
por: Mocellin, Lucas Pitrez, et al.
Publicado: (2022)

Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
por: Lu, Hong-Rui, et al.
Publicado: (2023)

Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
por: Moorhouse, Michelle A., et al.
Publicado: (2018)

Duration of antiretroviral regimens in treatment-experienced patients in clinical practice
por: Vilaplana, Vicente Escudero, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_992p9ad88klh0gvinh900083s8